Discontinued — last reported Q4 '21
Business Segments · Impairment of Intangible Assets (Excluding Goodwill)
Covance Drug Development — Impairment of Intangible Assets (Excluding Goodwill)
Labcorp Holdings Covance Drug Development — Impairment of Intangible Assets (Excluding Goodwill) remained flat by 0.0% to $7.95M in Q4 2021 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2020
Last reportedQ4 2021Feb 28, 2023
Rolls up toImpairment Charges
How to read this metric
An increase signals potential overvaluation of past acquisitions or deteriorating market conditions for specific service offerings.
Detailed definition
Represents the non-cash charge recognized when the carrying value of identifiable intangible assets, such as customer re...
Peer comparison
Common in CRO and life sciences sectors following large-scale M&A activity.
Metric ID:
lh_segment_covance_drug_development_impairment_of_intangible_assets_excluding_goodwillHistorical Data
3 periods
| Q2 '21 | Q3 '21 | Q4 '21 | |
|---|---|---|---|
| Value | $7.95M | $7.95M | $7.95M |
| QoQ Change | — | +0.0% | +0.0% |
Range$7.95M – $7.95M
Current Streak2+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — impairment of intangible assets (excluding goodwill)?
- Labcorp Holdings (LH) reported covance drug development — impairment of intangible assets (excluding goodwill) of $7.95M in Q4 2021.
- What does covance drug development — impairment of intangible assets (excluding goodwill) mean?
- The reduction in the recorded value of non-goodwill intangible assets due to a decline in their expected future value.